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Abstract 
Impairment of apoptosis is a hallmark of cancer. Tumor resistance to apoptosis usually caused by deregulation 
of the expression of BCL-2 family protein or mutation of the tumor suppressor gene p53. Over expression of 
Bcl-2 is commonly found in various types of cancer including breast cancer. Studies mentioned that analysis of 
Bcl-2 might predict response to selected endocrine and chemotherapies. This study is conducted to evaluate the 
correlation of BCL-2 mRNA expression and clinical response to neoadjuvant chemotherapy in breast cancer 
patients. Longitudinal study is used in this research, 30 subjects of breast cancer tissue samples 
prechemotherapy using cyclophosphamide-adriamycin-5FU regiment.  
------------------------------------------------------------------------ 
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Detection of mRNA expression of BCL-2 using qRT-PCR techniques.  Evaluation of clinical response to 
chemotherapy is using RECIST criteria. Mean value of BCL-2 mRNA expression in breast cancer patients was 
9.917± 2.568.  Mean value of BCL-2 mRNA expression of responsive group was 9.887± 2.731. Mean value of 
BCL-2 mRNA expression of nonresponsive group was 10.017±2.122. Mean value of responsive group were 
lower than nonresponsive group, but there was no significant correlation between baseline mRNA expression of 
BCL-2 with clinical response to chemotherapy, value of r=0.378, p=0.223 (p>0.05). this study shows that there 
was no significant correlation between baseline expression of mRNA BCL-2 with clinical response to 
chemotherapy.  
Keywords: Breast Cancer; Chemotherapy; Clinical Response; mRNA;  BCL-2; qRT-PCR. 
1. Introduction 
Cancer occurs due to disruption of balance of cell growth and death [1].  Tumor cells tend to interfere this 
balance by activating genes that promoting cell growth or activating genes that inhibit apoptosis [2, 3]. Tumor 
resistance to apoptosis usually caused by deregulation of the expression of BCL-2 family protein or mutation of 
the tumor suppressor gene p53 [4].  Over expression of Bcl-2 is commonly found in various types of cancer 
including breast cancer [5, 6].  BCL-2 is an important clinical prognostic marker in breast cancer,  patients with 
BCL-2 positive tend to relapse and shorter overall survival [7, 8]. Studies revealed that analysis of Bcl-2 might 
predict response to selected endocrine and chemotherapies [5-7, 9]. The aim of this study was to evaluate 
mRNA expression of BCL-2 prechemotherapy in association with breast cancer chemotheraphy response. 
2. Materials and Method 
2.1. Collection of Samples 
Study was conducted within a population of breast cancer patients who had been diagnosed through clinical and 
histopathology examination, which entered the Wahidin Sudiro Husodo Hospital in Makassar, South Sulawesi, 
Indonesia. All samples who fulfilled inclusion and exclusion criteria and willing to participate in the study and 
signing informed consent recruited as study samples. The samples consisted of 30 patients with breast cancer 
who have undergone combinations chemotherapy (combination of cyclophosphamide, adriamycin and 5FU).  
2.2. Nucleic Acid Isolation 
Nucleic acid was extracted from breast cancer tissue according to the diatom guanidinium isothiocyanate 
(GuSCN) method described by Boom and his colleagues 1990. Breast cancer tissue was mixed with 500μl of 
lysis buffer L6 (50mMTris-HCl, 5.25M GuSCN, 20mM EDTA, 0.1% Triton X100), vortexes vigorously, and 
centrifuged at 1,000 rpm for 5min. To obtain the nucleic acid, samples were lysed by incubation for 15 minutes 
at 18°C and 20μl of diatom suspension was added. The diatom containing the bound nucleic acid was 
centrifuged at 12,000 x g for 15 seconds to obtain diatom pellet. The diatom pellet was then washed with 
washing buffer L2 (5.25M GuSCN in 0.1M Tris-HCl, pH6.4), rinsed with 70% ethanol and acetone, and dried 
byincubation at 56°C for 10 minutes. The pellet was mixed with 60μl of 10mM Tris-HCl, pH 8.0, 1mM EDTA 
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buffer and the nucleic acid was eluted by incubation at 56°C for 10 minutes. After sedimentation of the diatom 
by centrifugation, the supernatant was collected and stored at -20°C until Real- Time PCR was performed [10]. 
2.3. Expression mRNA BCL-2 Genes by Real Time PCR 
Detection of mRNA expression of BCL-2 was done according to Real time PCR method previously describe by 
Arribas, 2007. Specific primers for mRNA BCL-2 were used described as table 1 [3]. 
Table 1: Sequence of primers and conditions used. 
Primer Sequence 5’ - 3’ Amplicon size Annealing 
temperature 
bcl-2a CCCTGTGGATGACTGAGTAC   
bcl-2b GCATGTTGACTTCACTTGTG 211 bp 540C 
AC 1 GACCCAGATCATGTTTGAG   
AC 2 GAGTTGAAGGTAGTTTCGTG 486 bp 550C 
Process  Time Temperature 
  RT-PCR  
              Inverse transcription           30 min   500C 
Activation prior to PCR           15 min   950C 
                    PCR 
Denaturalization           1 min   950C 
Annealing           30 sec   550C 
Extension           1 min   720C 
No. of cycles           34 cycles 
Final extension           10 min   720C 
 
Source [3].  
2.4. Data Analysis 
Data analysis using the SPSS (Statistical Package for Social Science) version 22. Normality of the samples were 
analyzed using shapiro wilk’s test. Analysis of patient’s characteristics and clinical response using chi square. 
Analysis of mean difference of BCL-2 mRNA expression between responsive and nonresponsive groups used 
wilcoxon test, to see the correlation using the pearson and spearman test. 
2.5. Ethical Clearence 
Ethical approval for this study was obtained from Research Ethics Committee, Faculty of Medicine, Hasanuddin 
University, Makassar, Indonesia.Number; 1581/H4.8.4.5.31/PP36-KOMETIK/2015 Register; UH15060492. 
3. Results 
We collected 30 samples of invasive breast carcinoma during July 2015 to August 2016, originated from 
Wahidin  Sudirohusodo Hospital. Youngest age of subject was 28 years and the oldest was 64 years old, the 
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mean age of subjects in this research was 50.3 years. Histopathologic grading obtained Low grade 6.7%, 
Moderate grade 63.3% and High grade 30%. Immunohistochemistry examination panel obtained ER+ 26.7%, 
PR+ 36.6%, HER2 56.6%. The clinical response to neoadjuvant chemotherapy; responsive as much as 76.7% 
and nonresponsive 23.3%. 
 
Table 2: Patients characteristic 
Characteristic   n (%) 
Age  
≤ 50 14 (46,7%) 
> 50 16 (53,3%) 
Grade  
Low Grade 2 (6,7%) 
Moderate Grade 19(63,3%) 
High Grade 9 (30 %) 
Immunohistochemistry  
ER 8 (26,7%) 
PR 11 (36,6%) 
HER2 17 (56,6%) 
Clinical response  
Responsive 23 (76,7%) 
Nonresponsive    7(23,3%) 
 
 
Figure 1: Amplification curve of BCL-2 mRNA expression 
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Table 3: Comparison expression of mRNA BCL-2 with clinical response to chemotherapy 
 
mRNA Expression 
Responsive 
(Mean±SD) 
(n=23) 
Non Responsive 
(Mean±SD) 
(n=7) 
 
Mean difference 
 
p 
     
BCL-2 9.887± 2.731 10.017±2.122 0.13 0.862 
 
p = * Wilcoxon test 
 
Mean value of BCL-2 mRNA expression in breast cancer patients was 9.917± 2.568.  Mean value of BCL-2 
mRNA expression of responsive group was 9.887± 2.731. Mean value of BCL-2 mRNA expression of 
nonresponsive group was 10.017±2.122. Mean value of responsive group were lower than nonresponsive group, 
but there was no significant in mean difference between baseline mRNA expression of BCL-2 with clinical 
response to chemotherapy, value of  p=0.862 (p>0.05). 
 
Table 4: Correlation of expression of mRNA BCL-2 with clinical response to chemotherapy 
  
 
mRNA Expression 
(Mean±SD) 
(n=30) 
Correlation with 
Chemotherapy response (r) p 
    
mRNA BCL-2  11.837±0.360  0.028 0.885* 
    
     p = * pearson 
 
There is a positive correlation between mRNA expression of  BCL-2 with clinical response to chemotherapy 
with value of r = 0.028, this correlation was insignificant with p = 0.885 (p>0.05).  
4. Discussion 
This study showed that there are no significant differences of BCL-2 mRNA expression between clinical 
response of responsive and nonresponsive group. Correlation test between mRNA expression of BCL-2 with 
clinical response was insignificant. It can be concluded from this study that the mRNA expression of BCL-2 is 
less influential on chemotherapy response. 
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Bcl-2 family proteins regulate cell death and proliferation, dysregulation of the process that occurs during 
oncogenic transformation. Thus, it is not surprising to find an expression of Bcl-2 in many cancers [11, 12]. Bcl-
2 is able to inhibit apoptosis resulting from a variety of different signals in the intracellular pathway [13, 14]. 
Bcl-2 has been found to inhibit apoptosis induced by chemotherapeutic drugs, including doxorubicin, in cancer 
cells [7, 15]. 
The study on breast cancer showed beneficial effects of Bcl-2 in disease free survival (DFS) and overall survival 
(OS). In these studies confirm the relevance of these prognostic factors p53 decrease compared to Bcl-2 in 
clinical practice[16]. Five studies of 11 212 women with early stage breast cancer concluded that Bcl-2 is an 
independent prognostic indicator that is advantageous to all types of early stage breast cancer. This study sets 
the rationale for the introduction of immunohisto chemistry Bcl-2 to improve the prognostic stratification of 
breast cancer [8] Study of 100 samples of breast cancer, comparing examination of BCL-2 with IHC and RT-
PCR techniques, found that expression of Bcl-2 in breast cancer by immunohisto chemistry or RT-PCR give 
very similar results, The results also suggest a link between gene expression of Bcl-2 with the favorable 
biological features and clinical tumor: the size of the tumor is small, nuclear low grade, hormone receptor 
expression, the absence of c-erb-B2 and mutant p53 expression, and the proliferation of low (an inverse 
correlation with the expression of Ki-67). This explains why the expression of Bcl-2 was consistently associated 
with a better prognosis for breast cancer in the previous report[3]. Research on breast cancer cases in 2749 
concluded that Bcl-2 and Ki-67 can be effectively combined to produce an index which is an independent 
predictor of survival in ER-positive breast cancer, increasing their potential prognostic utility [17]. 
Other studies found Bcl-2 expression was not significantly associated with pCR in TNBC patients, patients 
belonging to the Bcl-2-negative group tended to be more chemosensitive than those belonging to the Bcl-2-
positive group. This finding is in agreement with previous results showing that Bcl-2 could not predict response 
to neoadjuvan  chemoterapy [7, 18]. 
5. Conclusion 
BCL-2 mRNA expression in the responsive group lower than mRNA expression of BCL-2 in nonresponsive 
group. There is insignificant correlation between expression of mRNA BCL-2 baseline with chemotherapy 
response. 
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